
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is a leading pharmaceutical firm that is poised for strong growth thanks to its robust portfolio of key products and a growing presence in emerging markets. The company's recent strong quarterly results and a potential guidance upgrade for 2026 also support positive outlook. While there are some risks, such as potential patent challenges and a slower post-LOE growth profile, the company's overall favorable positioning makes it an attractive investment opportunity for long-term growth.
Bears say
Pfizer is facing major patent expirations for its top-selling drugs over the next few years, which will put significant pressure on its overall sales and profitability. This, combined with increasing competition in the pharmaceutical industry and potential challenges to its patents, creates a high level of uncertainty for the company's future growth prospects. Furthermore, concerns about Pfizer's reputation stemming from controversies around pricing and technology transfer for its COVID-19 vaccine have created additional risks for the company. These factors, along with Pfizer's limited M&A flexibility and behind-the-curve capabilities in manufacturing and market access, contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares